Compare PCRX & LGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | LGIH |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2010 | 2013 |
| Metric | PCRX | LGIH |
|---|---|---|
| Price | $23.50 | $46.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 5 |
| Target Price | $30.25 | ★ $75.90 |
| AVG Volume (30 Days) | ★ 516.5K | 409.4K |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | 0.07 | ★ 0.09 |
| Revenue | $541,533,000.00 | ★ $1,705,504,000.00 |
| Revenue This Year | $6.78 | $2.32 |
| Revenue Next Year | $8.54 | $17.94 |
| P/E Ratio | ★ $336.29 | $515.78 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $33.55 |
| 52 Week High | $27.64 | $69.42 |
| Indicator | PCRX | LGIH |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 55.32 |
| Support Level | $22.13 | $45.69 |
| Resistance Level | $24.20 | $49.51 |
| Average True Range (ATR) | 1.02 | 2.26 |
| MACD | -0.06 | -0.14 |
| Stochastic Oscillator | 42.93 | 75.68 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.